Red Light Holland rebrands to Rhelion, advances psychedelic drug development with Filament acquisition

Red Light Holland Corp. announced its rebranding to Rhelion Life Sciences effective August 4, 2026, reflecting its shift toward a science-driven life sciences company focused on naturally derived psychedelic medicines. The company completed the acquisition of Filament Health, significantly enhancing its pharmaceutical manufacturing, regulatory, and clinical research capabilities, including its patented botanical drug candidate PEX010. Fiscal 2026 saw the company streamline operations, expand its intellectual property portfolio, and support over 80 clinical studies globally. Looking ahead, Rhelion plans to advance drug candidates through later-stage clinical trials, expand manufacturing capacity, and pursue strategic partnerships to capitalize on growing regulatory acceptance of psychedelic therapies.